1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome
    Meeting Abstract

    Daud, A. I.; Hamid, O.; Ribas, A.; Hodi, F. S.; Hwu, W. J.; Kefford, R.; Wolchok, J.; Hersey, P.; Weber, J. S.; Joseph, R.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Carrasquillo, J. A.; Danila, D. C.; Beylergil, V.; O'Donoghue, J. A.; Cheal, S. M.; Ruan, S. T.; Pandit-Taskar, N.; Fox, J. J.; Fleming, S. E.; Zanzonico, P. B.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Cancer: Antitumour immunity gets a boost
    Journal Article

    Wolchok, J. D.; Chan, T. A.
    Nature (2014)

    Fulltext@MSK | Save
  • CTLA-4 antibodies: New directions, new combinations
    Journal Article

    Funt, S. A.; Page, D. B.; Wolchok, J. D.; Postow, M. A.
    Oncology (Norwalk) (2014)

    Fulltext@MSK | Save
  • Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway
    Journal Article

    Momtaz, P.; Postow, M. A.
    Pharmacogenomics and Personalized Medicine (2014)

    Fulltext@MSK | Save
  • Phase IB/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF Iinhibitor) in BRAF-mutant melanoma
    Meeting Abstract

    Taylor, M.; Sosman, J.; Gonzalez, R.; Carlino, M. S.; Kittaneh, M.; Lolkema, M. P.; Miller, W.; Marino, A.; Zhang, V.; Bhansali, S. G.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): Randomized comparison of two dosing schedules
    Meeting Abstract

    Robert, C.; Joshua, A. M.; Weber, J. S.; Ribas, A.; Hodi, F. S.; Kefford, R. F.; Daud, A.; Wolchok, J. D.; Hwu, W. J.; Gangadhar, T. C.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)
    Meeting Abstract

    Daud, A.; Hamid, O.; Robert, C.; Hodi, F. S.; Wolchok, J. D.; Hwu, W. J.; Weber, J. S.; Kefford, R.; Hersey, P.; Joshua, A. M.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Classification of current anticancer immunotherapies
    Journal Article

    Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J. M.; Buqué, A.; Senovilla, L.; Baracco, E. E.; Bloy, N.; Castoldi, F.; Abastado, J. P.; Agostinis, P.; more...
    Oncotarget (2014)

    Fulltext@MSK | Save